Prevalence of thyroid dysfunction in Egyptian chronic hepatitis C patients treated with Pegylated interferon and Ribavirin
Naguib, S., Hashem, A., Hammad, R., Hassanein, M., Omran, N. (2011). Prevalence of thyroid dysfunction in Egyptian chronic hepatitis C patients treated with Pegylated interferon and Ribavirin. EKB Journal Management System, 43(1), 199-211. doi: 10.21608/ejhm.2011.16777
Sherif M. Naguib; Ahmed M. Hashem; Radi Hammad; Mohamad A. Hassanein; Niveen E. Omran. "Prevalence of thyroid dysfunction in Egyptian chronic hepatitis C patients treated with Pegylated interferon and Ribavirin". EKB Journal Management System, 43, 1, 2011, 199-211. doi: 10.21608/ejhm.2011.16777
Naguib, S., Hashem, A., Hammad, R., Hassanein, M., Omran, N. (2011). 'Prevalence of thyroid dysfunction in Egyptian chronic hepatitis C patients treated with Pegylated interferon and Ribavirin', EKB Journal Management System, 43(1), pp. 199-211. doi: 10.21608/ejhm.2011.16777
Naguib, S., Hashem, A., Hammad, R., Hassanein, M., Omran, N. Prevalence of thyroid dysfunction in Egyptian chronic hepatitis C patients treated with Pegylated interferon and Ribavirin. EKB Journal Management System, 2011; 43(1): 199-211. doi: 10.21608/ejhm.2011.16777

Prevalence of thyroid dysfunction in Egyptian chronic hepatitis C patients treated with Pegylated interferon and Ribavirin

The Egyptian Journal of Hospital Medicine
Article 9, Volume 43, Issue 1, April 2011, Page 199-211  XML PDF (1.61 MB)
Document Type: Original Article
DOI: 10.21608/ejhm.2011.16777
View on SCiNiTO View on SCiNiTO
Authors
Sherif M. Naguib1; Ahmed M. Hashem1; Radi Hammad2; Mohamad A. Hassanein3; Niveen E. Omran4
1Internal Medicine Department,Faculty of Medicine,Cairo University.
2Internal Medicine Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
3Tropical Medicine Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
4Clinical Pathology Department, National Institute of Hearing & Speech, Giza, Egypt
Abstract
Background:Hepatitis C is a major cause of liver-related morbidity and mortality and represents a major public health problem in Egypt and worldwide. INF therapy is the most popular treatment for HCV. INF has many side effects most of them still under study. The development of thyroid dysfunction during IFN and Ribavirin combination therapy has been reported.
 
Aim:The aim of this study is to assess the Prevalence of thyroid dysfunction in Egyptian chronic hepatitis C patient treated with pegylated interferon and Ribavirin
 
Materials & Methods:The study was conducted in cooperation between Internal Medicine Department, Faculty of Medicine, Cairo University and Internal Medicine Department, out patients' clinic of National Hepatology and Tropical Medicine Research Institute (NHTMRI) in the period from January 2009 to June 2010. The current study included 200 patients who fulfilled the predesigned inclusion criteria. TSH was done pre treatment, every 3 months during treatment and 3 months following termination of treatment also were done for all cases. Also, FT3 and FT4 were done if there is abnormal TSH.
 
Results: The prevalence of thyroid dysfunction in chronic hepatitis C patients treated with pegylated INF and Ribavirin reaching 19% in this study.
 
 
Keywords
HCV- pegylated interferon-thyroid dysfunction
Statistics
Article View: 136
PDF Download: 295